Copyright
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Aug 15, 2021; 12(8): 1248-1254
Published online Aug 15, 2021. doi: 10.4239/wjd.v12.i8.1248
Published online Aug 15, 2021. doi: 10.4239/wjd.v12.i8.1248
Effect of inflammatory bowel disease treatments on patients with diabetes mellitus
Joshua Ashley Jack Bower, Lauren O'Flynn, David Aldulaimi, Department of Gastroenterology, South Warwickshire Foundation Trust, Warwick CV34 5BW, United Kingdom
Rakhi Kakad, Department of Endocrinology, South Warwickshire Foundation Trust, Warwick CV34 5BW, United Kingdom
Author contributions: Bower JAJ is the 1st author with assistance and review by O’Flynn L who is also the corresponding author; Kakad R and Aldulaimi D advised and reviewed the material.
Conflict-of-interest statement: No authors have any known conflicts of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Lauren O'Flynn, BSc, MBChB, MRCP, Doctor, Department of Gastroenterology, South Warwickshire Foundation Trust, Lakin Road, Warwick CV34 5BW, United Kingdom. l.oflynn@doctors.org.uk
Received: January 26, 2021
Peer-review started: January 26, 2021
First decision: March 30, 2021
Revised: April 13, 2021
Accepted: July 12, 2021
Article in press: July 12, 2021
Published online: August 15, 2021
Processing time: 195 Days and 1.6 Hours
Peer-review started: January 26, 2021
First decision: March 30, 2021
Revised: April 13, 2021
Accepted: July 12, 2021
Article in press: July 12, 2021
Published online: August 15, 2021
Processing time: 195 Days and 1.6 Hours
Core Tip
Core Tip: For patients with diabetes mellitus and inflammatory bowel disease, medication may influence glycaemic control. Furthermore, immunosuppressive therapy may modify the likelihood of other autoimmune conditions. Further studies on the effects of the various biological agents mentioned are required alongside any novel biologic therapy and the impact of dual biologic therapy in the future.